Effect of Fire Suppression and Emergency Duties on Vascular Function

Brief Summary

Official Title: “Effect of Fire Suppression and Emergency Duties on Vascular Function in Firefighters”

Firefighters are at increased risk of death from heart attacks when compared to other emergencyy service professionals whose jobs involve similar components such as emergency call-outs and shift work. In the largest analysis of cause of death amongst on-duty firefighters, firefighter deaths were classified according to the duty performed during the onset of symptoms or immediately prior to any sudden death. The majority of deaths due to a cardiovascular cause (i.e. heart attack) occurred during fire suppression whilst this activity represented a relatively small amount of a firefighters professional time. There was also a risk of death associated with other duties such as emergency non-fire response and physical exertion.

The investigators hypothesize that participation in active fire-fighting duties impairs blood vessel function and increases blood clot formation when compared with non-fire-fighting activities. In this study, healthy career firefighters will be assessed after three periods of duty: fire-suppression, emergency response without fire suppression and following a sedentary shift. The investigators will take blood samples to measure platelet activity (platelets are the particles in blood that help blood clot) and will examine how blood clots outside of the body. The investigators will then perform studies placing small needles in the arm to assess blood vessel function following these duties. By undertaking this comprehensive assessment of blood, blood vessel and heart function the investigators hope to understand the mechanisms whereby the risk of a heart attack, fatal or otherwise, is posed throughout these distinct duties that firefighters undertake on a daily basis.

  • Study Type: Observational
  • Study Design: Observational Model: Case-Crossover, Time Perspective: Prospective
  • Study Primary Completion Date: August 2014

Interventions Used in this Clinical Trial

  • Procedure: Forearm Vascular Study
    • Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
  • Procedure: Badimon Chamber
    • Ex-vivo assessment of thrombus formation using the Badimon Chamber

Arms, Groups and Cohorts in this Clinical Trial

  • Fire suppression
    • Firefighters will attend for vascular assessments following a night shift where they have performed fire suppression
  • Non-fire emergency duty
    • Firefighters will attend for vascular assessments following a night shift where they have had an emergency response without fire suppression eg. road traffic collision.
  • Sedentary shift
    • Firefighters will attend for vascular assessments following a night shift where they have remained sedentary throughout the shift.

Outcome Measures for this Clinical Trial

Primary Measures

  • Forearm blood flow measured by venous occlusion plethysmography in response to infused vasodilators
    • Time Frame: up to 12 hours after exposure
      Safety Issue?: No

Secondary Measures

  • Ex-vivo thrombus formation using the Badimon chamber
    • Time Frame: up to 12 hours after exposure
      Safety Issue?: No
  • Plasma t-PA and PAI concentrations following infusion of bradykinin
    • Time Frame: During forearm study, up to 12 hours after exposure
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria

  • Non-smoking healthy firefighters

Exclusion Criteria

  • Current smoker
  • History of lung or ischaemic heart disease
  • Malignant arrhythmia
  • Systolic blood pressure >190mmHg or <100mmHg
  • Renal or hepatic dysfunction
  • Previous history of blood dyscrasia
  • Unable to tolerate the supine position
  • Blood donation within the last 3 months
  • Recent respiratory tract infection within the past 4 weeks
  • Routine medication including aspirin and NSAIDs

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 60 Years

Are Healthy Volunteers Accepted for this Clinical Trial: Accepts Healthy Volunteers

Clinical Trial Investigator Information

  • Lead Sponsor
    • University of Edinburgh
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • David E Newby, MD PhD, Study Chair, University of Edinburgh
    • Nicholas L Mills, MBChB PhD, Study Director, University of Edinburgh
    • Amanda L Hunter, MBChB, Principal Investigator, University of Edinburgh
  • Overall Contact(s)
    • Amanda L Hunter, MBChB, +441312426437, amanda.hunter@ed.ac.uk

Source

Clinical Trials content is provided directly by the US National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of information about a specific clinical trial contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01805063